T2 Biosystems, Inc. TTOO shares are trading higher on Tuesday. Despite the gains, the stock is down nearly 100% year-to-date.
What To Know: Shares of T2 Biosystems took a nosedive in mid-October, hit hard by disappointing preliminary third-quarter total revenue data and the announcement of a reverse stock split.
However, last Monday, T2 Biosystems announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC which extends the interest-only period and the maturity date by one year from Dec. 31, 2024 to Dec. 31, 2025. It also permanently lowers the minimum cash covenant from $5,000,000 to $500,000. Also, last Tuesday, the company drew attention to new clinical data which it recently presented at the IDWeek 2023 conference.
While shares of the stock popped 14% on Tuesday, the move was not backed by strong volume. According to data from Benzinga Pro, the stock experienced below-average trading volume of 552,598 shares compared to its average volume of 1.16 million.
The stock's move may be related to its extremely high levels of short interest, with 831.77% of shares currently sold short.
Related Link: Investment Research Firm MSCI Reports Strong Q3 Growth With Significant Advances In ESG & Climate Segment
TTOO Price Action: Shares of TTOO were up 12.3% at $6.01 at the time of publication, according to Benzinga Pro.
Image by Triggermouse from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.